NCT06940830 - Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Hemophilia A

Interventions

DRUG

Efanesoctocog alfa

Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.

Trial Locations (21)

Unknown

NOT_YET_RECRUITING

Sobi Investigational Site, Zagreb

RECRUITING

Sobi Investigational Site, Brno

RECRUITING

Sobi Investigational Site, Ostrava

RECRUITING

Sobi Investigational Site, Prague

NOT_YET_RECRUITING

Sobi Investigational Site, Marseille

NOT_YET_RECRUITING

Sobi Investigational Site, Nantes

RECRUITING

Sobi Investigational Site, Berlin

RECRUITING

Sobi Investigational Site, Bonn

RECRUITING

Sobi Investigational Site, Frankfurt am Main

RECRUITING

Sobi Investigational Site, Hamburg

NOT_YET_RECRUITING

Sobi Investigational Site, Munich

RECRUITING

Sobi Investigational Site, Dublin

NOT_YET_RECRUITING

Sobi Investigational Site, A Coruña

NOT_YET_RECRUITING

Sobi Investigational Site, Barcelona

RECRUITING

Sobi Investigational Site, Málaga

RECRUITING

Sobi Investigational Site, Palma de Mallorca

RECRUITING

Sobi Investigational Site, Zaragoza

NOT_YET_RECRUITING

Sobi Investigational Site, Gothenburg

NOT_YET_RECRUITING

Sobi Investigational Site, Birmingham

RECRUITING

Sobi Investigational Site, Cardiff

RECRUITING

Sobi Investigational Site, London